USA Domestic Delivery,Canada Domestic Delivery,European Domestic Delivery

Medroxyprogesterone acetate (71-58-9)

Rating: SKU: 7207-92-3. Category:

AASraw is with synthesis and production ability from gram to mass order of Medroxyprogesterone acetate (71-58-9), under CGMP regulation and trackable quality control system.

blank

Product Description

 

Medroxyprogesterone acetate (71-58-9) video

 

 


 

Medroxyprogesterone acetate (71-58-9) Specification:

Chemical Structure: Product Name: Medroxyprogesterone acetate
Cas No.: 71-58-9
Molecular Formula: C24H34O4
Molecular Weight: 386.532
Standard: USP
Storage: Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years)..
Documents(COA & HPLC etc.): Available

 

Medroxyprogesterone acetate (71-58-9) Description:

Medroxyprogesterone Acetate is a synthetic, acetate derivative of the sex hormone progesterone. Medroxyprogesterone 17-acetate (NCI04). Medroxyprogesterone Acetate, also known as MPA, is a steroidal progestin, a synthetic variant of the steroid hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is almost always being referred to is MPA and not MP It is on the World Health Organization’s List of Essential Medicines, the most important medication needed in a basic health system.

 

Reference:

  • 1: Brind J, Condly SJ, Mosher SW, Morse AR, Kimball J. Risk of HIV Infection in Depot-Medroxyprogesterone Acetate (DMPA) Users: A Systematic Review and Meta-analysis. Issues Law Med. 2015 Autumn;30(2):129-39. Review. PubMed PMID: 26710371.
  • 2: Stanczyk FZ, Bhavnani BR. Reprint of “Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?”. J Steroid Biochem Mol Biol. 2015 Sep;153:151-9. doi: 10.1016/j.jsbmb.2015.08.013. Epub 2015 Aug 19. Review. PubMed PMID: 26291834.
  • 3: Ohyagi-Hara C, Sawada K, Aki I, Mabuchi S, Kobayashi E, Ueda Y, Yoshino K, Fujita M, Tsutsui T, Kimura T. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch Gynecol Obstet. 2015 Jan;291(1):151-7. doi: 10.1007/s00404-014-3417-z. Epub 2014 Aug 14. Review. PubMed PMID: 25118836.
  • 4: Stanczyk FZ, Bhavnani BR. Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? J Steroid Biochem Mol Biol. 2014 Jul;142:30-8. doi: 10.1016/j.jsbmb.2013.11.011. Epub 2013 Nov 26. Review. PubMed PMID: 24291402.